Atherosclerosis: From Molecular Mechanisms to Emerging Therapeutic Strategies

Atherosclerosis: From Molecular Mechanisms to Emerging Therapeutic Strategies

Abstract: Atherosclerosis, a chronic inflammatory disease of the arterial wall, remains a leading cause of morbidity and mortality worldwide. This report provides a comprehensive overview of atherosclerosis, ranging from its molecular underpinnings to the latest advancements in diagnosis, treatment, and prevention. We delve into the complex interplay of factors contributing to atherogenesis, including lipid metabolism, inflammation, endothelial dysfunction, and smooth muscle cell proliferation. Furthermore, we examine established and emerging therapeutic strategies, encompassing pharmacological interventions, lifestyle modifications, and novel approaches targeting specific molecular pathways. The report also addresses the critical role of personalized medicine and the potential of innovative imaging techniques in early detection and risk stratification. Finally, we discuss future directions in atherosclerosis research, focusing on the development of targeted therapies and preventive measures aimed at mitigating the global burden of this devastating disease.

1. Introduction

Atherosclerosis is a progressive disease characterized by the accumulation of lipids, inflammatory cells, and fibrous elements within the arterial wall, leading to the formation of atherosclerotic plaques. These plaques can narrow the arterial lumen, restricting blood flow and causing ischemia in the affected tissues. Furthermore, plaque rupture or erosion can trigger acute thrombotic events, such as myocardial infarction and stroke, representing the most devastating clinical manifestations of atherosclerosis. Despite significant advances in understanding the pathogenesis and management of atherosclerosis, it remains a major public health challenge, accounting for a substantial proportion of cardiovascular-related deaths and disability globally [1].

Traditional risk factors for atherosclerosis include hyperlipidemia, hypertension, diabetes mellitus, smoking, and family history of cardiovascular disease. However, it is increasingly recognized that atherosclerosis is a complex, multifactorial disease influenced by a combination of genetic, environmental, and lifestyle factors [2]. This complexity underscores the need for a comprehensive and personalized approach to the prevention and treatment of atherosclerosis.

This report aims to provide a detailed overview of atherosclerosis, exploring its underlying molecular mechanisms, risk factors, diagnostic modalities, therapeutic strategies, and future research directions. We will critically evaluate current knowledge and highlight emerging areas of investigation with the potential to transform the management of this pervasive disease.

2. Pathogenesis of Atherosclerosis: A Multifaceted Process

Atherosclerosis development is a complex and dynamic process involving multiple cell types and molecular pathways. The prevailing model of atherogenesis posits that endothelial dysfunction is the initiating event, triggered by risk factors such as hyperlipidemia, hypertension, and oxidative stress [3].

• 2.1 Endothelial Dysfunction:

The endothelium, the single-cell layer lining the inner surface of arteries, plays a crucial role in maintaining vascular homeostasis. Endothelial dysfunction is characterized by impaired production of nitric oxide (NO), a potent vasodilator and inhibitor of platelet aggregation. Reduced NO bioavailability leads to increased endothelial permeability, allowing lipoproteins, particularly low-density lipoprotein (LDL), to enter the arterial wall [4]. Furthermore, dysfunctional endothelium expresses increased levels of adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), which promote the recruitment of monocytes and T lymphocytes.

• 2.2 Lipid Accumulation and Oxidation:

Once inside the arterial wall, LDL particles undergo oxidative modification, a process that enhances their atherogenicity. Oxidized LDL (oxLDL) is recognized by scavenger receptors on macrophages, leading to their uptake and the formation of foam cells, the hallmark of early atherosclerotic lesions [5]. The accumulation of foam cells contributes to the formation of fatty streaks, the earliest visible lesions of atherosclerosis. In addition, oxLDL triggers inflammatory responses through the activation of Toll-like receptors (TLRs) on macrophages and endothelial cells.

• 2.3 Inflammation:

Inflammation plays a central role in all stages of atherosclerosis. Activated macrophages and endothelial cells release a variety of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), which further promote the recruitment and activation of immune cells [6]. T lymphocytes, particularly Th1 cells, contribute to plaque progression by releasing interferon-γ (IFN-γ), which activates macrophages and inhibits smooth muscle cell proliferation. Conversely, regulatory T cells (Tregs) exert anti-inflammatory effects by suppressing the activity of other immune cells.

• 2.4 Smooth Muscle Cell Proliferation and Migration:

Smooth muscle cells (SMCs), normally residing in the medial layer of the arterial wall, migrate into the intima in response to various stimuli, including platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β). These SMCs proliferate and synthesize extracellular matrix, contributing to the formation of a fibrous cap that covers the lipid-rich core of the atherosclerotic plaque [7]. The stability of the fibrous cap is a critical determinant of plaque vulnerability to rupture. A thin and inflamed fibrous cap is more prone to rupture, leading to acute thrombotic events.

• 2.5 Plaque Rupture and Thrombosis:

Plaque rupture, the most common cause of acute coronary syndromes, occurs when the fibrous cap overlying the lipid-rich core becomes weakened and tears. This exposes the highly thrombogenic core to the bloodstream, triggering platelet adhesion, activation, and aggregation, leading to thrombus formation [8]. Thrombus formation can partially or completely occlude the arterial lumen, resulting in ischemia and tissue damage. Plaque erosion, another mechanism of acute coronary syndromes, involves the superficial denudation of the endothelial layer, leading to platelet adhesion and thrombus formation without overt rupture of the fibrous cap.

3. Risk Factors and Genetic Predisposition

Several modifiable and non-modifiable risk factors contribute to the development and progression of atherosclerosis. These include:

• 3.1 Hyperlipidemia: Elevated levels of LDL cholesterol are a major risk factor for atherosclerosis. LDL cholesterol promotes endothelial dysfunction, lipid accumulation, and inflammation in the arterial wall. Conversely, high-density lipoprotein (HDL) cholesterol exerts protective effects by promoting cholesterol efflux from macrophages and inhibiting LDL oxidation [9].

• 3.2 Hypertension: High blood pressure damages the endothelium and increases its permeability to lipoproteins. Hypertension also promotes SMC proliferation and migration, contributing to plaque development [10].

• 3.3 Diabetes Mellitus: Diabetes is associated with accelerated atherosclerosis and increased risk of cardiovascular events. Hyperglycemia promotes endothelial dysfunction, oxidative stress, and inflammation. Advanced glycation end products (AGEs), formed by the non-enzymatic glycation of proteins and lipids, accumulate in the arterial wall and contribute to plaque instability [11].

• 3.4 Smoking: Cigarette smoking damages the endothelium, increases LDL oxidation, and promotes inflammation. Smoking also impairs HDL function and increases the risk of thrombosis [12].

• 3.5 Obesity: Obesity is associated with insulin resistance, dyslipidemia, and chronic inflammation, all of which contribute to atherosclerosis. Adipose tissue releases pro-inflammatory cytokines, such as TNF-α and IL-6, which promote systemic inflammation and endothelial dysfunction [13].

• 3.6 Genetics: Genetic factors play a significant role in determining an individual’s susceptibility to atherosclerosis. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with increased risk of cardiovascular disease, many of which are involved in lipid metabolism, inflammation, and blood pressure regulation [14]. For example, variants in the LDLR gene, encoding the LDL receptor, are associated with familial hypercholesterolemia and increased risk of premature atherosclerosis. Similarly, variants in the PCSK9 gene, encoding proprotein convertase subtilisin/kexin type 9, which regulates LDL receptor degradation, are associated with altered LDL cholesterol levels and cardiovascular risk. In recent years, polygenic risk scores (PRS) have gained attention for their potential to improve risk stratification by aggregating the effects of multiple genetic variants [15]. While promising, the clinical utility of PRS in predicting atherosclerotic risk remains an area of active research.

4. Diagnostic Methods

Several diagnostic methods are used to detect and assess the severity of atherosclerosis. These include:

• 4.1 Non-invasive Techniques:

  • 4.1.1 Ankle-Brachial Index (ABI): The ABI measures the ratio of blood pressure in the ankle to blood pressure in the arm. A low ABI indicates peripheral artery disease, a manifestation of atherosclerosis in the lower extremities.
  • 4.1.2 Carotid Intima-Media Thickness (CIMT): CIMT measures the thickness of the inner two layers of the carotid artery, the intima and media. Increased CIMT is a marker of early atherosclerosis and is associated with increased risk of cardiovascular events. It is relatively inexpensive and safe, however, its utility in predicting future events is debated [16].
  • 4.1.3 Coronary Artery Calcium (CAC) Scoring: CAC scoring uses computed tomography (CT) to detect and quantify calcium deposits in the coronary arteries. The CAC score is a strong predictor of cardiovascular events, with higher scores indicating greater risk [17].

• 4.2 Invasive Techniques:

  • 4.2.1 Coronary Angiography: Coronary angiography involves the injection of contrast dye into the coronary arteries, followed by X-ray imaging. This technique allows visualization of coronary artery blockages and is the gold standard for diagnosing coronary artery disease [18].
  • 4.2.2 Intravascular Ultrasound (IVUS): IVUS uses ultrasound to image the inside of the coronary arteries. IVUS provides detailed information about plaque size, composition, and stability. This allows for a more accurate assessment of lesion severity than angiography alone and helps guide interventional procedures.
  • 4.2.3 Optical Coherence Tomography (OCT): OCT uses light waves to create high-resolution images of the coronary arteries. OCT provides even greater detail than IVUS, allowing for the identification of thin-cap fibroatheromas, plaque erosion, and thrombus formation. It is increasingly used to assess plaque vulnerability and guide percutaneous coronary intervention (PCI) [19].

• 4.3 Emerging Imaging Techniques:

  • 4.3.1 Positron Emission Tomography (PET): PET imaging can be used to detect inflammation within atherosclerotic plaques. 18F-fluorodeoxyglucose (18F-FDG) is a glucose analog that is taken up by metabolically active cells, including inflammatory cells. PET imaging with 18F-FDG can identify plaques with increased inflammatory activity, which are more prone to rupture [20].
  • 4.3.2 Magnetic Resonance Imaging (MRI): MRI can be used to characterize plaque composition, including lipid content, fibrous cap thickness, and presence of hemorrhage. MRI also allows for the non-invasive assessment of endothelial function and arterial wall inflammation. However, spatial resolution remains a challenge.

5. Treatment Options

The treatment of atherosclerosis aims to reduce risk factors, slow plaque progression, and prevent acute cardiovascular events. Treatment options include:

• 5.1 Lifestyle Modifications:

  • 5.1.1 Diet: A heart-healthy diet, low in saturated and trans fats, cholesterol, and sodium, is essential for preventing and managing atherosclerosis. The Mediterranean diet, rich in fruits, vegetables, whole grains, and olive oil, has been shown to reduce cardiovascular risk [21].
  • 5.1.2 Exercise: Regular physical activity improves cardiovascular health by lowering blood pressure, improving lipid profiles, and increasing insulin sensitivity. Aim for at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic exercise per week [22].
  • 5.1.3 Smoking Cessation: Quitting smoking is one of the most effective ways to reduce cardiovascular risk. Smoking cessation programs and nicotine replacement therapy can help individuals quit smoking [12].

• 5.2 Pharmacological Interventions:

  • 5.2.1 Statins: Statins are the cornerstone of lipid-lowering therapy. Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, leading to decreased LDL cholesterol levels. Statins have been shown to reduce cardiovascular events in both primary and secondary prevention trials [23].
  • 5.2.2 Ezetimibe: Ezetimibe inhibits the absorption of cholesterol in the small intestine, leading to decreased LDL cholesterol levels. Ezetimibe can be used in combination with statins to further lower LDL cholesterol [24].
  • 5.2.3 PCSK9 Inhibitors: PCSK9 inhibitors are monoclonal antibodies that block the activity of PCSK9, a protein that promotes LDL receptor degradation. PCSK9 inhibitors significantly lower LDL cholesterol levels and have been shown to reduce cardiovascular events in high-risk patients [25].
  • 5.2.4 Antiplatelet Agents: Antiplatelet agents, such as aspirin and clopidogrel, inhibit platelet aggregation and reduce the risk of thrombosis. Antiplatelet therapy is used in both the acute treatment of acute coronary syndromes and in the secondary prevention of cardiovascular events [26].
  • 5.2.5 Antihypertensive Medications: Antihypertensive medications, such as ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and calcium channel blockers, are used to lower blood pressure and reduce the risk of cardiovascular events [10].

• 5.3 Surgical Interventions:

  • 5.3.1 Percutaneous Coronary Intervention (PCI): PCI involves the insertion of a catheter into a coronary artery, followed by balloon angioplasty and stent placement. PCI is used to open blocked coronary arteries and restore blood flow to the heart [18].
  • 5.3.2 Coronary Artery Bypass Grafting (CABG): CABG involves the surgical creation of new pathways for blood to flow around blocked coronary arteries. CABG is typically performed in patients with severe coronary artery disease involving multiple vessels [27].
  • 5.3.3 Carotid Endarterectomy (CEA): CEA involves the surgical removal of plaque from the carotid artery. CEA is used to prevent stroke in patients with significant carotid artery stenosis.
  • 5.3.4 Carotid Artery Stenting (CAS): CAS involves the insertion of a stent into the carotid artery to open a narrowed artery. CAS is an alternative to CEA for patients with carotid artery stenosis.

6. Emerging Therapeutic Strategies

Beyond established therapies, several novel approaches are being investigated for the treatment of atherosclerosis. These include:

• 6.1 Targeting Inflammation:

  • 6.1.1 Colchicine: Colchicine, an anti-inflammatory drug used to treat gout, has been shown to reduce cardiovascular events in patients with stable coronary artery disease. Colchicine inhibits the activation of the NLRP3 inflammasome, a key regulator of IL-1β production [28].
  • 6.1.2 IL-1β Inhibitors: IL-1β inhibitors, such as canakinumab, have been shown to reduce cardiovascular events in patients with prior myocardial infarction and elevated levels of high-sensitivity C-reactive protein (hsCRP). Canakinumab specifically targets IL-1β, a potent pro-inflammatory cytokine involved in atherosclerosis [29].

• 6.2 Gene Therapy:

  • 6.2.1 Gene editing of PCSK9: CRISPR-Cas9 technology has the potential to permanently lower LDL cholesterol through targeted disruption of the PCSK9 gene [30]. Clinical trials are underway to evaluate the safety and efficacy of this approach.
  • 6.2.2 Gene transfer of ApoA-I: Adeno-associated viral (AAV) vectors can be used to deliver genes encoding apolipoprotein A-I (ApoA-I), the major protein component of HDL. Increasing ApoA-I levels may promote cholesterol efflux from macrophages and reduce atherosclerosis [31].

• 6.3 MicroRNAs:

  • 6.3.1 miRNA Therapeutics: MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression. Certain miRNAs have been shown to play a role in atherosclerosis. Therapies targeting specific miRNAs, such as miR-33, have shown promise in preclinical studies [32].

• 6.4 Nanotechnology:

  • 6.4.1 Targeted Drug Delivery: Nanoparticles can be used to deliver drugs directly to atherosclerotic plaques. Nanoparticles can be engineered to target specific molecules expressed on endothelial cells or macrophages, allowing for targeted drug delivery and reduced systemic toxicity [33].

7. Prevention Strategies

Preventing atherosclerosis requires a multifaceted approach that addresses modifiable risk factors and promotes healthy lifestyle choices. Key preventive strategies include:

• 7.1 Primordial Prevention: Primordial prevention aims to prevent the development of risk factors for atherosclerosis in the first place. This involves promoting healthy eating habits, regular physical activity, and avoiding smoking from a young age [34].

• 7.2 Primary Prevention: Primary prevention aims to prevent the occurrence of cardiovascular events in individuals who have risk factors for atherosclerosis but have not yet developed clinical disease. This involves managing risk factors such as hyperlipidemia, hypertension, and diabetes through lifestyle modifications and medications [35].

• 7.3 Secondary Prevention: Secondary prevention aims to prevent recurrent cardiovascular events in individuals who have already experienced a cardiovascular event, such as a myocardial infarction or stroke. This involves aggressive risk factor management, antiplatelet therapy, and other medications to prevent further events [36].

8. The Role of Personalized Medicine

Atherosclerosis is a heterogeneous disease, with varying degrees of plaque burden, composition, and vulnerability. Personalized medicine approaches aim to tailor treatment strategies to the individual patient based on their specific risk factors, genetic profile, and disease characteristics. This may involve:

• 8.1 Risk Stratification: Using clinical risk scores, imaging techniques, and genetic markers to identify individuals at high risk of cardiovascular events.

• 8.2 Targeted Therapies: Selecting therapies based on individual patient characteristics and disease mechanisms. For example, patients with elevated Lp(a) may benefit from specific Lp(a)-lowering therapies.

• 8.3 Monitoring Treatment Response: Using biomarkers and imaging techniques to monitor treatment response and adjust therapy as needed.

9. Future Directions

Future research in atherosclerosis will focus on several key areas:

• 9.1 Elucidating the Molecular Mechanisms of Atherosclerosis: Further research is needed to fully understand the complex molecular mechanisms underlying atherogenesis. This will involve identifying novel therapeutic targets and developing more effective therapies.

• 9.2 Developing Novel Imaging Techniques: Improved imaging techniques are needed to detect and characterize atherosclerotic plaques at an early stage. This will allow for earlier intervention and prevention of cardiovascular events.

• 9.3 Identifying Novel Biomarkers: New biomarkers are needed to identify individuals at high risk of cardiovascular events and to monitor treatment response. This will require integrating omics data (genomics, proteomics, metabolomics) with clinical data.

• 9.4 Translating Basic Research into Clinical Practice: Efforts are needed to translate basic research findings into clinical practice. This will involve conducting well-designed clinical trials to evaluate the safety and efficacy of novel therapies.

10. Conclusion

Atherosclerosis remains a major global health challenge, despite significant advances in understanding its pathogenesis and management. A comprehensive approach to prevention and treatment is essential, encompassing lifestyle modifications, pharmacological interventions, and, in some cases, surgical procedures. Emerging therapeutic strategies targeting inflammation, gene expression, and drug delivery hold promise for future advancements in atherosclerosis management. The integration of personalized medicine approaches will further refine treatment strategies, optimizing outcomes for individual patients. Continued research efforts are crucial to unraveling the complexities of atherosclerosis and developing innovative solutions to mitigate its devastating impact on global health.

References

[1] Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.

[2] Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis. Nature. 2011;473(7347):317–25.

[3] Gimbrone MA Jr, Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–36.

[4] Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(9):1285–95.

[5] Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–55.

[6] Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S–60S.

[7] Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84(3):767–801.

[8] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326(4):242–50.

[9] Rader DJ, Hovingh GK. HDL metabolism and cardiovascular disease. N Engl J Med. 2014;370(10):900–9.

[10] Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89(2A):3A–9A.

[11] Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88.

[12] Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–7.

[13] Dandona P, Aljada A, Chaudhuri A, Mohanty D, Garg R. Metabolic syndrome and inflammation: diabetes, obesity, and atherosclerosis. Indian J Med Res. 2005;121(3):229–38.

[14] Lusis AJ, Attie AD, Reue K. Lipids and atherosclerosis. Nature. 2008;451(7181):807–15.

[15] Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2016;48(11):1349–54.

[16] Greenland P, Alpert JS, Beller GA, Benjamin EJ, Brill-Edwards P, Djoussé L, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50–e103.

[17] Budoff MJ, Shaw LJ, Berman DS, Nasir K, Gul KM, Raggi P, et al. Atherosclerotic Cardiovascular Disease Events by Sex and Age. Journal of the American College of Cardiology. 2018;72(25):3262-3272.

[18] Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(24):e123-e210.

[19] Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: expert consensus document from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2012;33(22):2838–47.

[20] Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography: J Am Coll Cardiol. 2002;39(1):15–22.

[21] Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90.

[22] Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The Physical Activity Guidelines for Americans. JAMA. 2018;320(19):2020-2028.

[23] Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.

[24] Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97.

[25] Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.

[26] Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

[27] Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(23):e652-e735.

[28] Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Colchicine reduces cardiovascular events in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847.

[29] Ridker PM, Everett BM, Thuren T, MacFadyen J, Chang WH, Ballantyne CM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131.

[30] Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Germain L, et al. In vivo CRISPR-Cas9 gene editing of PCSK9 in mice reduces LDL cholesterol and attenuates atherosclerosis. Circ Res. 2016;118(12):1902-9.

[31] Tuteja D, Farooqui AA, Singh S, Wagner MA, Singh AK, Kukreja RC. Gene therapy for cardiovascular disease: an update. Cardiovasc Drug Rev. 2006;24(1):3-26.

[32] Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328(5985):1570-3.

[33] Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Nanomedicine and its role in cardiovascular disease. Nat Rev Cardiol. 2011;8(9):525-32.

[34] Pearson TA, Blair SN, Daniels SR, Eckel RH, Fairly HB, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 update: Circulation. 2002;106(3):388–91.

[35] Greenland P, Alpert JS, Beller GA, Benjamin EJ, Brill-Edwards P, Djoussé L, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: Circulation. 2010;122(25):2748–64.

[36] Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation: Circulation. 2011;124(24):3313–40.